Axsome Therapeutics Inc

Executive Assistant to the CIO

Warren, New Jersey, United States

$60,000 – $80,000Compensation
Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical Technology, Healthcare AdministrationIndustries

Requirements

Candidates should possess a Bachelor’s degree and demonstrate at least five years of experience as an Executive Assistant, preferably supporting senior executives within a technology or pharmaceutical environment. Strong organizational skills, attention to detail, and the ability to manage multiple priorities simultaneously are essential. Familiarity with budget tracking, contract management, and administrative systems is desired.

Responsibilities

The Executive Assistant will provide comprehensive administrative support to the CIO and IT Leadership Team, including managing complex schedules, coordinating meetings across multiple time zones, preparing meeting materials, processing expense reports, and supporting travel arrangements. They will also assist with budget tracking, contract management, and invoice processing, while proactively identifying and implementing administrative systems and procedures to improve efficiency. Furthermore, the Executive Assistant will serve as an information resource on company policies and procedures, support adherence to regulatory requirements, and collaborate with internal departments and external resources on administrative matters.

Skills

Scheduling
Meeting Coordination
Budget Tracking
Contract Management
Administrative Systems
Expense Reports
Travel Arrangements
Microsoft Office Suite
Communication
Problem-Solving

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Key Metrics

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI